Upcoming Medical Conferences:
- An oral presentation highlighting Phase 1/2 results, including cohort 4, for AT-GAA for Pompe disease will be included at the 24th International
Congressof the World Muscle Societyto be held October 1-5, 2019in Copenhagen, Denmark.
° Oral Platform Presentation:
Friday, October 4, 10:00 a.m. CEST( 4:00 a.m. ET): First-in-human study of ATB200/AT2221 in patients with Pompe disease: 24-month functional assessment results from the ATB200-02 trial – Benedikt Schoser, MD, Friedrich-Baur Institute, Deptartment of Neurology, Ludwig-Maximilians-University of Munich, Germany.
- A poster presentation highlighting interim clinical results for the first gene therapy in CLN6 Batten disease will be included at the 48th Annual Meeting of the
Child Neurology Societyto be held October 23-26, 2019in Charlotte, NC.
° Poster Sessions:
Thursday, October 24, 4:00-5:30 p.m. ETand Friday, October 25, 7:00-8:15 a.m. ET: Interim Results from the First Clinical Gene Therapy Trial for CLN6 Batten Disease – Emily delos Reyes, MD, Pediatric Neurologist, Nationwide Children’s Hospital, Columbus, OH. (Poster #204)
Upcoming Investor Conferences:
John F. Crowley, Chairman and Chief Executive Officer, will participate in a fireside chat at the Cantor Fitzgerald Global Healthcare Conferencein New York, NYon Wednesday, October 2, 2019at 8:20 a.m. ET.
- Amicus team members and external speakers will present during the Amicus Analyst Day on
Thursday, October 10, 2019in New York, NYat 8:30 a.m. ET.
A live audio webcast of the presentations during the investor conferences and Amicus Analyst Day can be accessed via the Investors section of the
Vice President, Investor Relations
Executive Director, Corporate Communications
Source: Amicus Therapeutics, Inc.